CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces the appointment of Joan Stafslien to its Board of Directors, effective April 24, 2020 and expanding Board membership to seven. Ms. Stafslien brings to Ra Medical more than 25 years of legal and regulatory experience, primarily in the medical device industry, including serving as General Counsel at NuVasive, Inc. (Nasdaq: NUVA) and CareFusion Corporation.
“An accomplished medical technology executive with an impressive background in law and regulatory affairs, Joan brings to our Board highly relevant and additive expertise,” said Martin Colombatto, Chairman of Ra Medical Systems. “We look forward to calling upon her keen insights as we work toward driving adoption for our DABRA excimer laser system, expanding indications of use and building long-term shareholder value. We are pleased to welcome Joan to our Board.”
“I am excited to join the Ra Medical Systems Board and look forward to putting my experience and relationships to use in supporting the company’s mission of enhancing patient quality of life with its transformational photoablation technology,” said Ms. Stafslien.
Ms. Stafslien served as Executive Vice President, General Counsel and Corporate Secretary of NuVasive for two years, followed by another year as Executive Consultant. Previously, she was General Counsel, Corporate Secretary and Chief Compliance Officer of CareFusion Corporation, where she led the legal team through the company’s spin-off from Cardinal Health, Inc. in 2009 and its acquisition by Becton, Dickinson and Company in 2015. Prior to that, Ms. Stafslien served for five years as the Segment General Counsel of Cardinal Health’s Clinical Technologies and Services business, having joined that firm through its acquisition of Alaris Medical Systems. At Alaris, she served as Deputy General Counsel and Assistant Secretary. Prior to joining Alaris, she was an Associate at the law firm Brobeck, Phleger & Harrison.
About DABRA
DABRA is Ra Medical’s minimally invasive excimer laser system used by physicians as a tool in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease, a form of PAD, both above and below the knee. DABRA reduces all four plaque types into their fundamental chemistry, such as proteins, lipids and other chemical compounds, eliminating blockages by essentially dissolving them without generating potentially harmful particulates. DABRA employs photochemical ablation, or the removal of arterial tissue by using photons to clear blockages by breaking the bonds of the obstructing plaque. Unlike many treatments for PAD that may damage the arterial wall, DABRA quickly and photochemically dissolves plaque with minimal vascular trauma.
About Ra Medical Systems
Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases. In May 2017, the DABRA excimer laser system received FDA 510(k) clearance in the U.S. for crossing chronic total occlusions, or CTOs, in patients with symptomatic infrainguinal lower extremity vascular disease with an intended use for ablating a channel in occlusive peripheral vascular disease. Pharos excimer laser system is FDA-cleared and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma. DABRA and Pharos are both based on Ra Medical’s core excimer laser technology platform and deploy similar mechanisms of action. Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in controlled environments.
